The Institutional Biosafety Committee (IBC) is responsible for reviewing all research that involves the use of recombinant DNA in accord with the NIH Guidelines (NIH Guidelines for Research Involving Recombinant DNA Molecules revised March 2013) and ensuring that the proposed activities comply with the federal regulations governing them.
While the most scrutinized protocols are those dealing with environmental release of genetically engineered organisms or human gene therapy, all protocols including those using only laboratory- or greenhouse-contained experiments are closely examined. Clemson University requires that all faculty members/principal investigators (PI) file a protocol when using recombinant DNA molecules or organisms. All these research activities, regardless of the source of funding, must be reviewed by the IBC.
The University's Biosafety Officer, Kerri Kwist, must be consulted regarding any proposed use of potentially hazardous agents.
The IBC is a federally mandated review body established under the NIH Guidelines for Research Involving Recombinant DNA Molecules to provide local review and oversight of nearly all forms of research utilizing recombinant DNA. Over time, many institutions have chosen to assign their IBCs the responsibility of reviewing a variety of experimentation that involves hazardous biological materials (e.g., human bodily fluids, cell lines, infectious agents) and other potentially hazardous agents (e.g., carcinogens). Clemson University has elected to review and approve research utilizing recombinant DNA, hazardous biological agents (infectious or potentially infectious), select agents/toxins, the use of hazardous chemicals used in research with vertebrate animals, and the use of nanomaterials with the above categories.